Case Report
===========

A 56 years old indo-aryan black gentleman, farmer by occupation, occasional smoker and alcoholic for more than 20 years, presented to Haematology OPD with complains of weakness and easy fatigability for one month, he also had glandular swellings involving the neck, axilla and inguinal region. He noticed erythematous maculopapular rashes over both upper limbs, 2 days back. There was no history of fever, cough, bleeding, skeletal pain or jaundice. There was no involvement of the oral mucosa by the skin lesions. The past and family history was not significant. On examination, he had generalised lymphadenopathy and massive hepatosplenomegaly. The skin rashes ([Figure 1](#f1-mjhid-5-1-e2013020){ref-type="fig"}) were maculopapular erythematous, size varying from 4×5 cm to 10×8 cm without any initial itching, pain or secretion. Over 4 to 5 days, the rashes developed blackish discolouration, followed by bullae formation that eventually ruptured. The blood exam revealed anemia, thrombocytopenia and leucocytosis (WBC = 18000/mm^3^) with presence of atypical lymphoid cells on peripheral smear. The bone marrow examination showed 45% immature lymphoid cells, negative for MPO, SB, AP, NSE & PAS on cytochemistry. The bone marrow biopsy showed infiltration by atypical lymphoid cells. Immunophenotyping by flow cytometry of bone marrow showed positivity for co-expression of CD19/5, CD19, FMC7, Kappa clonality, CD25, HLADR, CD22, CD20, CD79b, SIgM and negative for co-expression of CD23/5, CD10, CD23, CD11C, CD103, CD2, CD3, CD34, SIgG, TdT. The axillary lymph node biopsy was suggestive of blastoid variant of mantle cell lymphoma, which showed immunopositivity for CD 20, CD43, Cyclin D1, BCL-2, BCL-6 and immunonegative for CD5, CD3, CD10, CD23. The skin biopsy from the left arm maculopapular lesion (including both healthy and affected area) showed congested vessels along with extravasations of RBC in the dermis without any atypical lymphoid cells ([Figure 2a](#f2a-mjhid-5-1-e2013020){ref-type="fig"} and [2b](#f2b-mjhid-5-1-e2013020){ref-type="fig"}). He received R-CHOP chemotherapy and has undergone debridement ([Figure 3](#f3-mjhid-5-1-e2013020){ref-type="fig"}) for the skin lesions. Gradually, after 5 cycles of chemotherapy, he has attained complete remission of skin lesions along with disappearance of lymphadenopathy, organomegaly and normalisation of the hemogram.

Discussion
==========

Mantle cell lymphoma (MCL) is a malignant tumor derived from B cells in the mantle zone of lymphoid follicles characterized by specific pathologic, immunophenotypic and molecular genetics features, and usually takes an aggressive clinical course, defined in the World Health Organization (WHO) classification.[@b1-mjhid-5-1-e2013020]--[@b3-mjhid-5-1-e2013020] Histologically, it shows a diffuse or nodular monotonous proliferation of small lymphoid cells with scant cytoplasm and irregular nuclear contours in lymphnodes.

Immunophenotypically, the tumor cells are positive for B-cell markers CD79a, CD19, CD20 and CD22 as well as CD5, and are usually negative for CD10 and CD23.[@b5-mjhid-5-1-e2013020],[@b6-mjhid-5-1-e2013020] The majority of MCL have an associated cytogenetic abnormality t(11,14) (q13;q32) translocation, which causes a juxtaposition of the *CCND-1* gene on chromosome 11 with the immunoglobulin heavy chain gene on chromosome 14, resulting in an over expression of cyclin D1 protein, that leads to a positive signal for transition to the S phase.[@b7-mjhid-5-1-e2013020]--[@b9-mjhid-5-1-e2013020] Cyclin D1 over expression is considered to be an important diagnostic marker for MCL.[@b10-mjhid-5-1-e2013020]

MCL frequently involves extra nodal organs, particularly the bone marrow, gastrointestinal tract and Waldeyer's ring; thus it has been considered in the past as an extracutaneous lymphoma. However, MCL rarely affects the skin. In two large series of 121 and 59 cases of MCL, only 3 and 2 patients respectively had skin lesions, respectively.[@b3-mjhid-5-1-e2013020],[@b4-mjhid-5-1-e2013020] To the best of our knowledge, only 18 cases of mantle cell lymphoma with skin manifestation have been reported in English literature ([Table 1](#t1-mjhid-5-1-e2013020){ref-type="table"}).[@b11-mjhid-5-1-e2013020],[@b12-mjhid-5-1-e2013020] The commonly reported sites of skin involvement in MCL are trunk (60%), face (30%) followed by arm (20%), thigh, leg & scalp.[@b11-mjhid-5-1-e2013020],[@b12-mjhid-5-1-e2013020] Skin lesions manifested as nodular lesions in 6 patients (34%), macular or maculopapular lesions, as in our case, in 6 (34%), tumoral or infiltrated plaques in 4 (21%), and subcutaneous nodules in 2 (11%).[@b11-mjhid-5-1-e2013020],[@b12-mjhid-5-1-e2013020]

In most of the reported cases of skin manifestations of MCL, skin lesion has shown infiltration by atypical lymphoid cells, while a reactive cutaneous eruption, simulating insect bites, has been only incidentally described in association with MCL.[@b11-mjhid-5-1-e2013020],[@b13-mjhid-5-1-e2013020]--[@b15-mjhid-5-1-e2013020] The skin involvement, even if rare, has been most frequently reported in the blastoid variant of MCL as in our case; when present the skin localizations are disseminated and associated with a poor prognosis.[@b11-mjhid-5-1-e2013020],[@b12-mjhid-5-1-e2013020],[@b16-mjhid-5-1-e2013020] Although, large reactive skin lesions have not been reported previously, the absence of atypical lymphoid cells and the complete remission with chemotherapy suggest that the skin lesions should be considered in the present case as reactive to mantle cell lymphoma; however, the presence of hidden malignant cells in the lesion cannot be excluded. The prognosis of MCL with skin localizations is particularly poor; aggressive chemotherapy may improve the survival rate.[@b12-mjhid-5-1-e2013020] As cutaneous lesions can be the first manifestation of MCL, awareness of MCL is crucial for dermatologists and haematologists to establish an early diagnosis and perform an appropriate treatment.
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  No   Author    Age/Sex   Location                    Clinical presentation          Extracutaneous Involvement                     Stage   Prognosis
  ---- --------- --------- --------------------------- ------------------------------ ---------------------------------------------- ------- ----------------------------------------
  1    Ellison   66M       Temple                      Macular skin lesions           LN, liver, spleen, lung, pleural cavity, CNS   IV      D (55d; after initial hospitalization)
  2    Geerts    65F       Forehead                    Nodules                        LN, BM                                         IVA     D (1.5y; after diagnosis)
  3    Geerts    77F       Back, breast, arm           Tumoral plaques                Bronchus wall                                  IVA     
  4    Bertero   51M       Breast                      Subcutaneous nodule            LN, liver, spleen                              IVA     A (17y; after onset)
  5    Bertero   78F       Breast, back                Nodules                        None                                           I E     D (3y; after diagnosis)
  6    Bertero   43M       Back, face, arm             Infiltrated plaques            LN, liver, spleen                              IVA     A
  7    Bertero   22M       Breast                      Nodules                        None                                           I E     A
  8    Marti     61F       Abdomen                     Tumoral plaque                 LN, BM, tonsils                                IVA     D (15m; after diagnosis)
  9    Moody     47M       Ear                         Nodules                        LN, BM                                         IVA     A (3y; after onset)
  10   Dubus     56M       Breast, back                Erythematous papules           LN, BM, PB                                     IVA     D (1y; after treatment)
  11   Dubus     89M       Breast, back, abdomen       Infiltrated purpuric papules   LN, BM, PB                                     IVA     D (5d; after diagnosis)
  12   Dubus     72M       Face, breast, arm, axilla   Subcutaneous nodules           LN, BM                                         IVA     A (1y; after treatment)
  13   Sen       85M       Leg                         Macular rash                   LN. BM, buccal mucosa                          IVB     D (20m; after onset)
  14   Sen       76M       Thigh                       Nodule                         None                                           I E     A (30m; after onset)
  15   Sen       56M       Chest                       Nodules                        BM, GI                                         IVA     A (21m; after onset)
  16   Sen       57M       Legs                        Maculopapular rash             LN, BM, PB                                     IVB     D (9m; after onset)
  17   Sen       61M       Flank back, thigh           Plaques                        LN, BM, PB leptomeninges                       IVB     D (15m; after onset)
  18   Motegi    62 M      Back, upper extremities     nodules                        LN, Spleen, gastric mucosa, tonsils            IVA     A (4 month, after treatment)
